Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
L Emmett, K Willowson, J Violet, J Shin… - Journal of medical …, 2017 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
Theranostics in nuclear medicine practice
A Yordanova, E Eppard, S Kürpig… - OncoTargets and …, 2017 - Taylor & Francis
The importance of personalized medicine has been growing, mainly due to a more urgent
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
M Sathekge, F Bruchertseifer, O Knoesen… - European journal of …, 2019 - Springer
Background A remarkable therapeutic efficacy has been demonstrated with 225 Ac-prostate-
specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant …
specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant …
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
Y Liu, T Watabe, K Kaneda-Nakashima… - European Journal of …, 2022 - Springer
Purpose Fibroblast activation protein (FAP), which has high expression in cancer-associated
fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study …
fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study …
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
MP Yadav, S Ballal, RK Sahoo, SN Dwivedi… - American Journal of …, 2019 - ajronline.org
OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment …
Abstract Background 177 Lu–PSMA-617 (Lu-PSMA) is an emerging therapy in men with
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential …
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential …
Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy
R Seifert, K Seitzer, K Herrmann, K Kessel… - …, 2020 - pmc.ncbi.nlm.nih.gov
Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific
membrane antigen (PSMA) in vivo, which is the target molecule of 177Lu-PSMA-617 (Lu …
membrane antigen (PSMA) in vivo, which is the target molecule of 177Lu-PSMA-617 (Lu …
A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177–labeled prostate-specific membrane antigen–targeted radioligand therapy in …
Context Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge.
Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy …
Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy …
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Purpose Up to 30% of patients with castration-resistant prostate cancer (CRPC) do not show
any response to the first cycle of radioligand therapy (RLT) with [177 Lu] Lu-PSMA-617 (Lu …
any response to the first cycle of radioligand therapy (RLT) with [177 Lu] Lu-PSMA-617 (Lu …